Chidamide

Chidamide
Clinical data
Trade names	Epidaza
Identifiers
	IUPAC name N-(2-Amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide;
CAS Number	1616493-44-7 ;
PubChem CID	9800555;
ChemSpider	7976319;
UNII	87CIC980Y0;
Chemical and physical data
Formula	C22H19FN4O2
Molar mass	390.4 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1;
	InChI InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+; Key:WXHHICFWKXDFOW-BJMVGYQFSA-N;

Chidamide (Epidaza) is a histone deacetylase inhibitor (HDI) developed wholly in China.[1] It was also known as HBI-8000.[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.[3]

Chidamide is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and has orphan drug status in Japan.[2] As of April 2015 it is only approved in China.[1]

Chidamide is being researched as a treatment for pancreatic cancer.[4][5][6] However, it is not US FDA approved for the treatment of pancreatic cancer.

References

"China's First Homegrown Pharma". April 2015.
2
HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai. Feb 2016
Qiao, Z (2013-04-26). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochem Biophys Res Commun. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
Guha, Malini (2015-04-01). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews Drug Discovery. 14 (4): 225–226. doi:10.1038/nrd4583. PMID 25829268.
Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[SA2015-1] "China's First Homegrown Pharma". April 2015.

[FBT2016-2] 2

[3] HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai. Feb 2016

[Qiao2013-4] Qiao, Z (2013-04-26). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochem Biophys Res Commun. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.

[Guha2015-5] Guha, Malini (2015-04-01). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews Drug Discovery. 14 (4): 225–226. doi:10.1038/nrd4583. PMID 25829268.

[6] Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.